NASDAQ:IMA ImageneBio Q4 2024 Earnings Report $4.87 +0.02 (+0.37%) Closing price 09/23/2026 03:58 PM EasternExtended Trading$4.86 -0.01 (-0.27%) As of 09/23/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ImageneBio EPS ResultsActual EPS-$2.16Consensus EPS -$2.76Beat/MissBeat by +$0.60One Year Ago EPSN/AImageneBio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImageneBio Announcement DetailsQuarterQ4 2024Date3/11/2025TimeBefore Market OpensConference Call DateWednesday, March 5, 2025Conference Call Time6:00PM ETConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) ImageneBio Earnings HeadlinesImageneBio, Inc. (NASDAQ:IMA) Receives $29.00 Average PT from AnalystsSeptember 20, 2026 | americanbankingnews.comImageneBio Corporate Event Calendar | NASDAQ:IMASeptember 13, 2026 | benzinga.comElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point. | Porter & Company (Ad)ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSeptember 8, 2026 | markets.businessinsider.comImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New YorkSeptember 8, 2026 | globenewswire.comImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 17, 2026 | markets.businessinsider.comSee More ImageneBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email. Email Address About ImageneBioImageneBio (NASDAQ:IMA) is a biotechnology company focused on precision oncology and the development of blood-based tools for cancer research and clinical care. The company’s work centers on analyzing tumor-derived genetic material found in blood, with the goal of providing noninvasive information about a patient’s cancer. Its technology is designed to support tumor profiling, biomarker identification, and the monitoring of disease over time. By combining molecular analysis with computational methods, ImageneBio aims to help physicians and researchers characterize tumors, identify potentially relevant treatment options, and evaluate changes in tumor biology. Publicly available information about ImageneBio’s commercial portfolio, geographic operations, and leadership is limited. The company is associated with the ticker symbol IMA on the Nasdaq Stock Market.View ImageneBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
